AREDS2 Supplementation and Lifestyle Management for Age‑Related Macular Degeneration

Nutritional Supplementation Recommendations

The American Academy of Ophthalmology recommends the AREDS2 formulation (vitamin C, vitamin E, zinc, copper, lutein, and zeaxanthin) for patients at high risk of AMD progression; this recommendation is based on high‑quality randomized controlled trial evidence. 1
AREDS2 supplementation should be offered to older adults with intermediate AMD (bilateral soft drusen, large drusen ≥ 125 µm, or pigmentary changes) because it reduces the risk of progression to late AMD by roughly 25 %. [2][3]1
AREDS2 supplementation should also be offered to patients with advanced AMD in one eye (geographic atrophy or neovascular AMD) for the same approximate 25 % reduction in progression risk. [1][2]

Smoking cessation is mandatory for AMD patients; smoking is a major, dose‑dependent risk factor for AMD progression, with risk increasing proportionally to pack‑years smoked. Evidence comes from large prospective cohort studies. [1][2][3][4]
Maintaining a healthy body‑mass index lowers the risk of AMD progression; elevated BMI independently raises progression risk, with observational data showing a 3‑ to 5‑fold increase in advanced AMD incidence when combined with other unhealthy behaviors. [2][3]5
Regular comprehensive eye examinations are essential because early AMD is often asymptomatic; timely detection enables initiation of AREDS2 supplementation when it is most beneficial. This recommendation follows guideline consensus. [1][2]3

The primary adverse effect of AREDS2 supplementation is gastrointestinal discomfort; no major safety concerns have been identified in the trial data. (Safety information derived from the AREDS2 trial; strength of evidence: randomized controlled trial). 1

If all ≈ 8 million Americans aged ≥ 55 years with intermediate AMD or monocular advanced AMD took AREDS2 supplements, more than 300 000 individuals could delay disease progression and associated vision loss, representing a substantial public‑health benefit. (Model based on trial efficacy; strength of evidence: high‑quality RCT extrapolation). [1][2]3